Table 2.

Adverse events recorded and broken down by age (>or < 75 years) and in relation to previous treatment with docetaxel (yes or not).

Adverse events N (%)	Patients treated with radium-223 (N = 38)
	Previous docetaxel use (N = 24)				No previous docetaxel use (N = 14)
	Age > 75 yr (N = 12)		Age < 75 yr (N = 12)		Age > 75 yr (N = 8)		Age < 75 yr (N = 6)
	All Grade	G3–5	All grade	G3–5	All grade	G3–5	All grade	G3–5
Hematological adverse events
Anemia	8 (21.05%)	5 (13.1%)	4 (10.5%)	2 (5.2%)	1 (2.6%)	1 (2.6%)	1 (2.6%)	0 (0%)
Neutropenia	2 (5.2%)	1 (2.6%)	0 (0%)	0 (0%)	1 (2.6%)	1 (2.6%)	0 (0%)	0 (0%)
Thrombocytopenia	3 (7.8%)	1 (2.6%)	0 (0%)	0 (0%)	1 (2.6%)	0 (0%)	0 (0%)	0 (0%)
Nonhematological adverse events
Constipation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (2.6%)	0 (0%)	0 (0%)	0 (0%)
Diarrhea	3 (7.8%)	1 (2.6%)	1 (2.6%)	0 (0%)	2 (5.2%)	1 (2.6%)	1 (2.6%)	0 (0%)
Nausea/Vomiting	1 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)
Fatigue	2 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)	2 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)
Anorexia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Weight decreased	1 (2.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Fever	2 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)	1 (2.6%)	0 (0%)
Peripheral edema	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (2.6%)	0 (0%)